PRNP and neurodegenerative disease: Both, verification and implementation of any PrP-modifying therapy in pre-clinical and clinical trials (Minikel et al. 2019) as well as urgently required improved (and earlier) diagnosis of specific neurodegenerative diseases, will critically depend on the assessment of reliable biomarkers.